Girding For New GERD Therapies

Two biotech companies, Addex Pharmaceuticals and XenoPort, are in a tight race to develop successors to the generic or soon-to-be-generic blockbuster proton pump inhibitors. As the firms' drugs proceed through clinical trials, their respective outcomes are an object lesson for biotechs and pharmaceutical companies looking to enter a crowded space already well served by existing medicines.

Two biotech companies, Addex Therapeutics and XenoPort Inc., are in a tight race to develop successors to the generic or soon-to-be-generic blockbuster proton pump inhibitors omeprazole (Prilosec) and lansoprazole (Prevacid). As the firms’ drugs proceed through clinical trials, their respective outcomes—both clinically and in terms of their partnering potential—are an object lesson for biotechs and pharmaceutical companies looking to enter a crowded space already well served by existing medicines.

Both companies are developing molecules that target transient lower esophageal sphincter relaxation (TLESR), the underlying mechanism implicated in gastroesophageal reflux...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo